Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year

This article was originally published in The Pink Sheet Daily

Executive Summary

With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).

You may also be interested in...



Barr Allegra-D Generic Receives Final Approval

A launch of the generic fexofenadine/pseudoephedrine combination would be "at risk" because of ongoing patent litigation with Sanofi-Aventis. Final ANDA approval follows resolution of a dispute between Barr and FDA over 180-day exclusivity for the product.

Barr Allegra-D Generic Receives Final Approval

A launch of the generic fexofenadine/pseudoephedrine combination would be "at risk" because of ongoing patent litigation with Sanofi-Aventis. Final ANDA approval follows resolution of a dispute between Barr and FDA over 180-day exclusivity for the product.

Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal

Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel